Amelioration of hyperlipidemia and coronary risk markers with supplementation of *Cinnamomum zeylanicum* bark extracts on Triton WR-1339 induced hyperlipidemia in Wistar albino rats

S. L. D. V. Ramana Murty Kadali¹, B. H. M. R. K. Gupatha²*, Vijay Kumar M.³, Revanasiddappa B. C.⁴

¹, ²Assistant Professor, ³Associate Professor, ⁴Dept. of Pharmacology, ³,⁴Dept. of Pharmaceutical Chemistry, ¹Modern Institute of Medical Sciences, Indore, Madhya Pradesh, ²IQ City Medical College, Durgapur, West Bengal, ³,⁴NGSM Institute of Pharmaceutical Sciences, Mangalore, Karnataka, India

*Corresponding Author:
Email: manikanta05bayya@gmail.com

Abstract

Introduction: *Cinnamomum zeylanicum* bark used in Indian traditional medicine to treat hyperlipidemia and cardiovascular diseases. Hyperlipidemia is a major risk factor for coronary heart disease and metabolic syndrome.

Objective: The present study was to evaluate the antihyperlipidemic effect of ethanolic and aqueous extracts of *Cinnamomum zeylanicum* bark against Triton induced hyperlipidemia in Wistar albino rats.

Materials and Methods: Thirty rats (200-230gm) were randomly divided into five groups of six rats in each, received standard diet and water daily. Normal control (5% CMC), positive control (Triton 400mg/kg), standard control (atorvastatin 40mg/kg), ethanolic and aqueous extracts of Cinnamon groups (CZEE and CZAE 500 mg/kg of each) were assigned and treated respectively. All the groups except normal control were administered triton to induce hyperlipidemia. Both the standard and plant extracts were administered for seven days orally. At the end of the study, fasting blood was collected and serum was separated out to estimate the lipid profile and various markers of coronary heart diseases.

Results: Post supplementation of atorvastatin, CZEE and CZAE significantly (P<0.05) ameliorated the hyperlipidemia and decreased the risk of cardiovascular diseases in triton induced hyperlipidemic rats.

Conclusion: From the observations, it can be concluded that supplementation of Cinnamon extracts can significantly decline the lipid abnormalities and ameliorate the markers of coronary heart disease and provides the scientific evidence for their traditional claims. Further molecular studies are warranted to evaluate the causative molecule for antihyperlipidemic effect.

Keywords: Hyperlipidemia, Cardiovascular diseases, Triton, Atorvastatin and Cinnamon extracts.

Introduction

Hyperlipidemia is a metabolic disorder characterized by elevated levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), Very LDLC (VLDL-C) and triglycerides (TGs) with a subsequent decrease in the levels of high-density lipoprotein cholesterol (HDL-C) in the systemic circulation.¹ Consumption of high fat or fructose diet, lifestyle modification, age, genetics, smoking, hypertension, type 2 diabetes and other precipitating factors play a significant role in causing aberrant lipid profile. Dyslipidemia is a major cause of atherosclerotic cardiovascular disease (ASCVDs), such as Coronary heart disease (CHD), ischemic cerebrovascular disease (CBVD) and peripheral vascular disease (PVD).² Cardiovascular diseases (CVDs) are the major leading cause of worldwide morbidity and mortality among the adults. A 20% reduction in blood cholesterol level can decrease about 31% of CHD incidence and 33% of its mortality rate.³

Hyperlipidemia is a primary target, to find a remedial measure for the treatment of CVD. Hypercholesteremia and hypertriglyceridemia are the potential risk factors either alone or together, responsible for the development of coronary artery disease and its progression towards atherosclerosis.⁴ Deposition of elevated LDL-C in the arterial endothelial spaces causes vascular toxicity and responsible for atherosclerosis, hypertension and obesity etc. In hyperlipidemia, both enzymatic as well as non-enzymatic antioxidative defense systems such as superoxide dismutase (SOD), lipid peroxidation (LPO), ascorbic acid and reduced glutathione (GSH) levels were reduced, leading to the generation of Reactive oxygen species (ROS) and which mediates vascular damage.⁵

Currently available hypolipidemic agents like statins, fibrates, bile acid sequestrants and niacin were used either alone or in combinations to treat dyslipidemic disorders. On long-term use, they are well known to cause various side effects (includes hepatotoxicity, myopathy, hypercholemic acidosis, dyspepsia, flushing, and pruritus), lacks safety, cost-effectiveness and with poor patient’s compliance.² It indicates, there is a high demand in search of drugs with antihyperlipidemic, antioxidant activities with no or lesser side effects, and which can be accomplished by the phytomedicine.⁶ Recent literature reveals that the consumption of phyto-active constituents like polyphenols can abbreviate the risk of hyperlipidemia and associated complications. So, bioactive
pharmaceutical research. They will serve as leads for the design and development of effective, safe and economic drugs.6-7

Cinnamon bark is a spice, most commonly used as the aromatic and flavoring agent. Since ancient times, it is being used in traditional folkloric and ayurvedic medicine for treatment of several ailments. The bark is smooth, light to dark brown, with a strong, pleasant smell, spicy and a burning taste. There are two important varieties of cinnamon: Cinnamomum zeylanicum and Cinnamomum cassia. Cinnamomum zeylanicum (family- Lauraceae) is reported to have numerous pharmacological activities which includes anti-diabetic,8 hepatoprotective,9 anti-oxidant,10 anti-inflammatory,11 anti-nociceptive,12 anti-fungal,13 anti-microbial,14 anti-viral,15 and anti-fertility.16 Literature unveils the lipid lowering effects of C. zeylanicum17-19 and C.cassia20 were carried out with different doses in diabetic (streptozotocin and alloxan) and hyperlipidemic (high fat or and fructose diet) models. Most of the research work accomplished on cinnamon species in hyperlipidemia due to an underlying disease of a multi-factorial origin. In the present study, aqueous and ethanolic extracts of C. zeylanicum with a tolerable dose were used, for a shorter duration in a particular hyperlipidemic model induced with Triton-WR 1339 and results were compared with atorvastatin.

Material and Methods

Animals

Wistar albino rats of either of sex, weighing 200-230gm were selected. All the animals were housed in polypropylene cages and a room temperature of 24±2°C and 12 hrs light and dark cycles were maintained throughout the period. The animals were allowed to acclimatize to the environment for seven days, prior to the experimentation. The ethical clearance was obtained from the Institutional animal ethics committee (IAEC), prior to the beginning of the experimentation with Ref. no. of NGSMIPS/IAEC/December-2016/36. Handling and care of laboratory animals were carried according to CPCSEA guidelines, Ministry of Forests & Environment and Government of India.

Table 1: Animal grouping and treatment schedule in Triton induced hyperlipidemic rats respectively

<table>
<thead>
<tr>
<th>Groups (n=6)</th>
<th>Treatment schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>I: Normal control</td>
<td>Received 5% CMC solution orally</td>
</tr>
<tr>
<td>II: Positive control</td>
<td>Received Triton (400mg/kg, i.p.) + 5% CMC solution orally</td>
</tr>
<tr>
<td>III: Standard control</td>
<td>Received Triton + Atorvastatin (40mg/kg, p.o)</td>
</tr>
<tr>
<td>IV: CZEE</td>
<td>Received Triton + Cinnamon ethanolic extract (500mg/kg, p.o)</td>
</tr>
<tr>
<td>V: CZAE</td>
<td>Received Triton + Cinnamon aqueous extract (500mg/kg, p.o)</td>
</tr>
<tr>
<td>Post-treatment for 7 days after induction of hyperlipidemia in albino rats. CZEE-Cinnamon zeylanicum Ethanolic Extract, CZAE- Cinnamon zeylanicum Aqueous Extract.</td>
<td></td>
</tr>
</tbody>
</table>

Most of the research works on plant extracts were carried out with a single daily dosing.22-23 may be to enhance the tolerability and to avoid multiple-dose cumulative toxicity24-25 of an unknown pharmacokinetic profile of a phytoconstituents, irrespective of screening of any pharmacological activities in animal models.

Collection of blood: On the eighth day,26 2-3ml of fasting blood was collected by the retro-orbital puncture under mild ether anesthesia. Blood samples were centrifuged at 3000 RPM, with the help of ultracentrifuge to separate the serum and stored at -20°C until further biochemical analysis.27-28

Biochemical estimation: Serum total cholesterol, triglycerides were estimated by the method of CHOD-PAP and high-density lipoprotein-cholesterol by the method of GPO-PAP by using Semi-autoanalyzer and with the help of diagnostic kits. VLDL-cholesterol level was determined by Friedewald’s formula.29

\[ \text{VLDL-C} = \text{TG}/5 \]
LDL cholesterol was calculated as: \(29\) LDL-C = TC – HDL-C – VLDL-C.

**Determination of cardiac risk indices**

Atherogenic index and Percentage of protection were calculated by using the formula:

\[
\text{Atherogenic index} (\text{AI}) = \left(\frac{\text{TC} - \text{HDL-C}}{\text{HDL-C}}\right)
\]

\[
\% \text{ Protection} = \frac{\text{AI of experimental control} - \text{AI of treated control}}{\text{AI of control}} \times 100.
\]

**Antiatherogenic index (AAI)** = HDL-C X 100 / TC-HDL-C.

**Dyslipidemic marker or Coronary risk index (CRI)** = TC-C / HDL-C.

**Cardiovascular risk index (CVRI)** = LDL-C / HDL-C.

**Statistical Analysis:** All the values were expressed as Mean ± SEM and subjected to One-way analysis of variance followed by Tukey’s multiple comparisons by using graph pad prism 5.0. P<0.05 is considered as the level of significance.

### Results

**Effect on serum lipid Profile in hyperlipidemic rats**

Positive control showed a significant increase in the levels of TC as compared to normal control rats. The rats treated with atorvastatin, CZEE and CZAE showed a significant decrease in the level of TC as compared to the positive control group after seven days of the respective treatments (Table 2). Both the CZEE and CZAE produce comparable effects with atorvastatin.

**Effect on serum level of LDL-C**

LDL-C levels were significantly increased in positive control when compared with normal control rats. Treatment with atorvastatin showed a significant decrease in the positive control, whereas both cinnamon extracts fail to reduce LDL-C levels in hyperlipidemic rats (Table 2).

**Effect on AI, % of protection and AAI**

AI is significantly elevated in positive control when compared with normal control. Treatment with atorvastatin and both cinnamon extracts significantly decreases the AI as compared to positive control. Moreover, positive control also exhibits a significant decrease of AAI in comparison with normal control rats. Similarly, in comparison with positive control, treatment with atorvastatin and both extracts of cinnamon, was potentially alleviated the AAI. The extracts showed similar effects with atorvastatin in elevating the HDL-C in hyperlipidemic rats.

**Effect on serum level of VLDL-C**

Positive control exhibited a significant increase of VLDL-C levels, as compared to normal control groups. Whereas, administration of atorvastatin, CZEE and CZAE, significantly decreased the levels of VLDL-C in comparison with positive control group. Treatment with CZEE and CZAE decreased VLDL-C in hyperlipidemic rats and effects were comparable with atorvastatin (Table 2).

<table>
<thead>
<tr>
<th>Groups</th>
<th>TC  mg/dl</th>
<th>TG  mg/dl</th>
<th>HDL mg/dl</th>
<th>VLDL mg/dl</th>
<th>LDL mg/dl</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control</td>
<td>79.93 ± 3.12 b, c</td>
<td>145.6 ± 7.37 b</td>
<td>39.87 ± 3.62</td>
<td>29.11 ± 1.47 b</td>
<td>10.95 ± 3.67 b, c</td>
</tr>
<tr>
<td>Positive control</td>
<td>254.4 ± 8.701 a, c</td>
<td>434.8 ± 65.6 a, c</td>
<td>22.49 ± 2.91 c</td>
<td>86.96 ± 13.11 a, c</td>
<td>144.9 ± 9.85 a, c</td>
</tr>
<tr>
<td>Standard control</td>
<td>166.3 ± 9.84 a, b</td>
<td>167.8 ± 8.41 b</td>
<td>51.87 ± 3.23 b</td>
<td>33.56 ± 1.68 b</td>
<td>80.87 ± 10.99 a, b</td>
</tr>
<tr>
<td>CZEE</td>
<td>181.1 ± 17.85 a, b</td>
<td>182.1 ± 10.60 b</td>
<td>43.77 ± 7.41 b</td>
<td>36.43 ± 2.12 b</td>
<td>100.9±26.47 a</td>
</tr>
<tr>
<td>CZAE</td>
<td>204.5 ± 6.11 a, b</td>
<td>165.8 ± 11.79 b</td>
<td>51.88 ± 3.25 b</td>
<td>37.16 ± 2.39 b</td>
<td>115.4±7.28 a</td>
</tr>
</tbody>
</table>

Values are expressed in Mean ± SE. P<0.05 is considered as the level of significance.

a Statistically significant from the normal control group.
b Statistically significant from the positive control group.
c Statistically significant from standard drug group.
above results depict, that increase of AI and decrease of % of protection as well of AAI in the positive control, suggests the development of atherogenesis followed by the cardiovascular events in hyperlipidemic rats. Whereas, treatment with drugs could reverse the atherogenesis and offers protection from cardiovascular risks in hyperlipidemic rats (Fig. 1, 2 and 3).

![Image](72x35 to 433x46)

**Fig. 1:** The effect of CZEE and CZAE on AI in hyperlipidemic rats. Mean ± SE (n=6), a: Statistically significant from the normal control group; b: Statistically significant from the positive control group; c: Statistically significant from standard drug group

![Image](72x459 to 294x628)

**Fig. 2:** The effect of CZEE and CZAE on % protection in hyperlipidemic rats. Mean ± SE (n=6)

![Image](72x228 to 290x378)

**Fig. 3:** The effect of CZEE and CZAE on AAI in hyperlipidemic rats. Mean ± SE (n=6). a: Statistically significant from the normal control group; b: Statistically significant from the positive control group; c: Statistically significant from standard drug group

**Effect on a Dyslipidemic marker or Coronary risk index**

The TC-C/HDL-C ratio is a marker of dyslipidemia, was significantly increased in the positive control, as compared to the normal control rats. Whereas, treatment with atorvastatin, CZEE and CZAE significantly decreased TC/HDL ratio in comparison to the positive control. Correction of dyslipidemia is the most significant result of treatment with CZEE, CZAE and effects are comparable to atorvastatin. (Fig. 4)

![Image](318x559 to 537x720)

**Fig. 4:** The effect of CZEE and CZAE on CRI in hyperlipidemic rates. Mean ± SE (n=6). a: Statistically significant from the normal control group; b: Statistically significant from the positive control group; c: Statistically significant from the standard drug group

**Cardiovascular risk index (CVRI)**

CVRI is a ratio of LDL-C and HDL-C, was significantly higher in the positive control rats as compared to normal control rats. Treatment with atorvastatin, CZEE and CZAE significantly decreased CVRI in comparison with positive control rats.
Atorvastatin profoundly decreased cardiovascular risk than the cinnamon extracts in hyperlipidemic rats. (Fig. 5).

Fig. 5: The effect of CZEE and CZAE on CVRI in hyperlipidemic rats. Mean ± SE (n=6). a: Statistically significant from the normal control group; b: Statistically significant from the positive control group; c: Statistically significant from the standard drug group

Discussion

Hyperlipidemia is divided into primary and secondary subtypes. Primary hyperlipidemia is usually due to genetic (familial) causes and secondary (acquired) hyperlipidemia develops due to other underlying diseases. Normally the body balances the lipid metabolism between synthesis and degradation. When the balance is lost, lipid abnormalities can cause deleterious effects on arteries, blood pressure, body weight, insulin sensitivity, glucose utilization and fatty changes in the liver, etc. Increased levels of TC and lipoproteins (LDL-C and HDL-C) have a close correlation with the cardiovascular risks. TG’s are composed of fatty acids and glycerol, circulate in the blood and stored in adipose tissue. In dyslipidemia, TG’s get deposited in the cytoplasm of non-adipose cells, such as hepatocytes, muscle fibers and then closely linked to peripheral insulin resistance. When a high-fat diet is taken, TG’s (and glucose) levels were significantly elevated and the body gradually processes the fat efficiently and their levels were decreased in a physiological manner. Approximately 65 percent of TC is carried by low-density lipoproteins. LDL-C (known as “bad” cholesterol) is potentially harmful, gets deposited onto the walls of arteries to undergo atherosclerosis. The particle size of cholesterol is utmost important because, larger particles are less dangerous than the smaller ones which readily penetrate the arterial wall and gets oxidized, which leads to the endothelial dysfunction, atheromatous plaque formation, ischemia and finally causes infraction. Atherogenesis is a process of oxidative modification of LDL, which triggers multiple pathological events leading to atherosclerosis. Clinically reported that HDL-C (known as good cholesterol) is inversely related to TC and a decreased level of HDL-C can hasten the development of atherosclerosis leading to ischemic heart diseases, by impairing the cholesterol clearance from the arterial wall. Now a days, many models are available, of which dietary manipulation or chemical induced hyperlipidemia is most commonly used animal models. Chronic consumption of high-fructose and or fat-rich diet-induced hyperlipidemias were associated with several manifestations of metabolic syndrome and type-2 diabetes. Whereas, Triton WR-1339 or tyloxa pol is a non-ionic detergent, widely used to induce acute hyperlipidemia in animals. The advantage of this model is the quick induction of hyperlipidemia, requires only a shorter treatment period and reproducibility, hence gained its popularity for the screening of natural or chemical entities for the hypolipidemic or antihyperlipidemic activity. Triton produces hypercholesterolemia and hypertriglyceridemia by accelerating hepatic cholesterol synthesis and blocking the clearance of TG-rich lipoproteins. Triton WR1339 acts as a surfactant and block the uptake of lipoproteins from the circulation through extra-hepatic pathways and increases the circulatory lipoprotein levels. Additionally, it increases the HMG-CoA reductase activity in the liver. The biphasic nature of tritonna-induced hyperlipidemia was helpful in understanding the mode of action of lipid-lowering agents. Drugs interfering with lipid biosynthesis or uptake will be active in the synthesis phase and metabolism will be active in the excretory phase. Moreover, the use of triton WR 1339 induced hyperlipidemia is an important approach to screen the action of hypolipidemic drugs but also as a mean for elucidating lipid metabolism.

Research in recent years had been directed towards dietary supplements bearing antihyperlipidemic and antioxidants effects, derived from plant sources are beneficial in reducing atherogenic fractions and cardiovascular risks. There are plethora of studies, which has investigated the medicinal plants for their acute hypolipidemic activity in Triton WR-1339-induced hyperlipidemic animals. In the present study, atorvastatin (40 mg/kg) is taken as standard drug, act as an HMG-CoA reductase inhibitor. It decreases hepatic cholesterol synthesis, increases LDL receptor expression on hepatocyte membranes and promotes LDL-C catabolism. By which, it reduces the TC, LDL-C and also the rate of production of VLDL-C by the liver. Hence, it’s effective in treating patients with hypertriglyceridemia and hypercholesterolemia. Treatment with atorvastatin and both extracts of cinnamon exhibited a significant decrease in TC and improves HDL-C levels, indicates a significant improvement in the AI. AI indicates the deposition of atherosclerotic plaque or foam cells or fat infiltration in heart, coronaries, aorta,
liver and kidneys results in oxidative damage to the organs. It correlates with the size of the pro-and antitherapeutic lipoprotein particles and is known to predict a CRI (TC/C-HDL-C ratio). AI value was higher in the positive control than normal control, is an indication of cardiovascular risk. Whereas, CRI was significantly reduced in treated groups with either atorvastatin, CZAE, and CZEE. Percentage of protection exhibited by all the treatment groups, confirms ameliorative effects of these drugs in the hyperlipidemia and associated cardiovascular risks in the present model.

Antitherapeutic index (AAI) of positive control rats exhibited a bad impact of triton-induced dyslipidemia on the cardiovascular system. Supplementation of both extracts of cinnamon to hyperlipidemic rats, significantly alleviated the CVRI (LDL-C/HDL-C ratio), a marker of coronary heart diseases. The results, exhibit that reduction of these indices in treated hyperlipidemic rats strongly supported the belief that dietary supplementation with cinnamon may reduce the risk of developing cardiac diseases due to dyslipidemia.

The potential effects of *Cinnamomum zeylanicum* bark aqueous and ethanolic extracts on hyperlipidemia may be attributed to a decrease in the cholesterol synthesis and an increase in cholesterol excretion as well the expression of LDL receptors with subsequent metabolism and a parallel increase in HDL-C. The lipid-lowering effect of the selected model still there is some void existing to establish the same results to claim the qualitative results and a clear mechanistic approach is needed by conducting PK/PD profile which is planned to execute in the future.

**Conclusion**

Identifying the medicinal herbs effective in hyperlipidemia’s is utmost important in terms of safety and cost-effective. Our findings suggest that cinnamon could be used as a dietary supplement in the treatment of hyperlipidemia, obesity and cardiac diseases. The antitherapeutic activity could be the due presence of aldehydes, chalcones, flavonoids, and polyphenols will claim the major credit in the protective mechanism. The precise mechanism of their biological effects *vivo* deserves further molecular investigation.

**Acknowledgments**

The authors are thankful to the co-workers of the Department and Management for facilitating to carry out this project expeditiously. We are also grateful to Greenchem, Bangalore for providing *C. Zeylanicum* extracts as gift sample.

**Funding:** No funding sources  
**Conflict of interest:** None declared

**References**


15. Tamam S Ma, Abd el Hamid M Sb, Samah M Helmyc, Marwa A Nakhriy. “The Anti-viral and Immunomodulatory activity of *Cinnamomum zeylanicum*
against Newcastle disease virus in chickens”.


